according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 650786-00016 Date of first issue: 05/02/2016 4.1

#### **SECTION 1. IDENTIFICATION**

**Daptomycin Injection Formulation** Product name

No data available Other means of identification

# Manufacturer or supplier's details

Company name of supplier Merck & Co., Inc Address 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone 908-740-4000 Emergency telephone 1-908-423-6000

E-mail address EHSDATASTEWARD@merck.com

## Recommended use of the chemical and restrictions on use

Recommended use **Pharmaceutical** Restrictions on use Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

#### GHS classification in accordance with the Hazardous Products Regulations

- repeated exposure

(Dermal)

Specific target organ toxicity : Category 2 (muscle, Kidney, Nervous system)

#### **GHS** label elements

Hazard pictograms



Signal Word Warning

**Hazard Statements** H373 May cause damage to organs (muscle, Kidney, Nervous

system) through prolonged or repeated exposure in contact with

skin.

**Precautionary Statements** Prevention:

P260 Do not breathe dust.

Response:

P314 Get medical attention if you feel unwell.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

# Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

#### Components

	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Daptomycin	No data availa- ble	103060-53-3	>= 80 - <= 100 *

Actual concentration or concentration range is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May cause damage to organs through prolonged or repeated

exposure in contact with skin.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

: Treat symptomatically and supportively.

### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

Notes to physician

media

Specific hazards during fire

fighting

: None known.

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not get on skin or clothing. Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation.

according to the Hazardous Products Regulations



# Daptomycin Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 650786-00016 Date of first issue: 05/02/2016 4.1

> Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Daptomycin	103060-53-3	TWA	800 µg/m3 (OEB	Internal
	1		<b>4</b>	

**Engineering measures** Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat. Hygiene measures

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment. appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

Appearance : lyophilized cake

Color : light brown

Odor : No data available

Odor Threshold : No data available

pH : 4.5 - 5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

Particle size : No data available

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

### **SECTION 11. TOXICOLOGICAL INFORMATION**

## Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

# **Acute toxicity**

Not classified based on available information.

### Skin corrosion/irritation

Not classified based on available information.

## **Components:**

## Daptomycin:

Species : Rabbit

Result : Mild skin irritation

## Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### Daptomycin:

Species : Rabbit

Result : Mild eye irritation

## Respiratory or skin sensitization

### Skin sensitization

Not classified based on available information.

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

#### Respiratory sensitization

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

Daptomycin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Hamster

Application Route: Intraperitoneal injection

Result: negative

## Carcinogenicity

Not classified based on available information.

#### Reproductive toxicity

Not classified based on available information.

#### **Components:**

#### Daptomycin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 150 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Intravenous injection

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

Developmental Toxicity: NOAEL: 75 mg/kg body weight Result: No significant adverse effects were reported

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 75 mg/kg body weight Result: No significant adverse effects were reported

## STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (muscle, Kidney, Nervous system) through prolonged or repeated exposure in contact with skin.

#### **Components:**

# Daptomycin:

Target Organs : muscle, Kidney, Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

#### Components:

#### Daptomycin:

Species: DogNOAEL: 20 mg/kgLOAEL: 40 mg/kgApplication Route: IntravenousExposure time: 3 MonthsTarget Organs: Skeletal muscle

Species : Monkey
NOAEL : 10 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog

Application Route : Intravenous Exposure time : 28 Days

Target Organs : Skeletal muscle, Nervous system

Symptoms : muscle twitching

Species : Juvenile dog LOAEL : 50 mg/kg Application Route : Intravenous Exposure time : 28 Days

Target Organs : Skeletal muscle, Nervous system

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

#### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

Daptomycin:

General Information : Symptoms: Rash, Diarrhea, vaginitis

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### **Ecotoxicity**

No data available

### Persistence and degradability

No data available

## **Bioaccumulative potential**

No data available

# Mobility in soil

No data available

### Other adverse effects

No data available

## **SECTION 13. DISPOSAL CONSIDERATIONS**

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

## International Regulations

### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

# Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **Domestic regulation**

#### **TDG**

Not regulated as a dangerous good

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

#### Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : compile the Material Safety

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

according to the Hazardous Products Regulations



# **Daptomycin Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 4.1 09/30/2023 650786-00016 Date of first issue: 05/02/2016

Data Sheet cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8